VNRX•VolitionRx reduced CEO Cameron Reynolds’ annual base salary to $236,970.50 from $355,456, effective November 1, 2026. The agreement extends temporary salary cuts and provides no additional equity compensation.
VolitionRx reduced CEO Cameron Reynolds’ annual base salary to $236,970.50 from $355,456, effective November 1, 2026, under a November 10 agreement extending temporary salary cuts as part of cost-reduction measures. The compensation committee may restore some or all of his salary when financial stability improves, without retroactive effect; termination-related payments and pension allowances remain based on his full contractual annual base salary of $473,941.
